logo
Twitter
Discord
Email
logo
Agilent Technologies, Inc.

Agilent Technologies, Inc.

NYSE•A
CEO: Mr. Rodney Gonsalves
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1999-11-18
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
Contact Information
5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, United States
800-227-9770
www.agilent.com
Market Cap
$40.65B
P/E (TTM)
33.5
vs Industry 35.8
Dividend Yield (TTM)
0.7%
52W High
$153.84
52W Low
$96.43
52W Range
82%
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$1.74B+10.14%
4-Quarter Trend

EPS

$1.18+21.65%
4-Quarter Trend

FCF

$573.00M+59.17%
4-Quarter Trend

Earnings Highlights

Key Highlights

No Data Available

Risk Factors

No Data Available

Outlook

No Data Available

Peer Comparison

Revenue (TTM)

Cardinal Health, Inc.CAH
$234.31B
-1.8%
Takeda Pharmaceutical Company LimitedTAK
$29.98B
+1.5%
IQVIA Holdings Inc.IQV
$15.90B
+3.6%

Gross Margin (Latest Quarter)

Edwards Lifesciences CorporationEW
77.6%
-0.9 pp
Takeda Pharmaceutical Company LimitedTAK
65.2%
+10.8 pp
Haleon plcHLN
64.5%
-0.2 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IDXX$50.29B51.364.4%37.1%
EW$49.01B11.841.2%5.2%
CAH$45.33B28.3-55.7%16.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+0.7%
Moderate Growth
4-Quarter Net Income CAGR
-1.4%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow Performance

Research & Insights

Reports
All Years
  • Form 10-Q - Q2 2025

    Period End: Apr 30, 2025|Filed: Jun 2, 2025|
    Revenue: $1.67B+6.0%
    |
    EPS: $0.75-28.6%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Jan 31, 2025|Filed: Mar 3, 2025|
    Revenue: $1.68B+1.4%
    |
    EPS: $1.12-5.9%
    Miss
  • Form 10-K - FY 2024

    Period End: Oct 31, 2024|Filed: Dec 20, 2024|
    Revenue: $6.51B-4.7%
    |
    EPS: $4.44+5.2%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Jul 31, 2024|Filed: Aug 30, 2024|
    Revenue: $1.58B-5.6%
    |
    EPS: $0.97+155.3%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Apr 30, 2024|Filed: Jun 3, 2024|
    Revenue: $1.57B-8.4%
    |
    EPS: $1.05+2.9%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Jan 31, 2024|Filed: Mar 5, 2024|
    Revenue: $1.66B-5.6%
    |
    EPS: $1.19+0.0%
    Meet
  • Form 10-K - FY 2023

    Period End: Oct 31, 2023|Filed: Dec 20, 2023|
    Revenue: $6.83B-0.2%
    |
    EPS: $4.22+0.7%
    Miss
  • Form 10-Q - Q3 2023

    Period End: Jul 31, 2023|Filed: Aug 31, 2023|
    Revenue: $1.67B-2.7%
    |
    EPS: $0.38-65.5%
    Miss